Mizuho Has Lowered Expectations for Hologic (NASDAQ:HOLX) Stock Price

Hologic (NASDAQ:HOLX - Get Free Report) had its price target lowered by stock analysts at Mizuho from $90.00 to $87.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an "outperform" rating on the medical equipment provider's stock. Mizuho's price objective indicates a potential upside of 10.41% from the company's previous close.

Several other research analysts also recently weighed in on the company. Leerink Partners dropped their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. StockNews.com lowered shares of Hologic from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 27th. Royal Bank of Canada lifted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday. Citigroup downgraded shares of Hologic from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $89.25.

Hologic Trading Down 5.9 %

Shares of HOLX traded down $4.92 during trading hours on Tuesday, reaching $78.80. 3,428,381 shares of the company traded hands, compared to its average volume of 1,591,221. The company's fifty day moving average price is $81.06 and its two-hundred day moving average price is $78.08. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $18.30 billion, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. Hologic has a 12 month low of $66.93 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same period in the prior year, the firm posted $0.89 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. Equities research analysts predict that Hologic will post 4.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

Institutional investors and hedge funds have recently modified their holdings of the stock. Norden Group LLC boosted its stake in Hologic by 44.0% during the first quarter. Norden Group LLC now owns 5,480 shares of the medical equipment provider's stock worth $427,000 after buying an additional 1,675 shares during the period. Fidelis Capital Partners LLC purchased a new stake in Hologic in the 1st quarter worth about $63,000. Daiwa Securities Group Inc. boosted its position in shares of Hologic by 0.8% during the first quarter. Daiwa Securities Group Inc. now owns 36,160 shares of the medical equipment provider's stock valued at $2,819,000 after buying an additional 270 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of Hologic by 22.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 40,286 shares of the medical equipment provider's stock worth $3,141,000 after acquiring an additional 7,432 shares during the last quarter. Finally, Central Pacific Bank Trust Division purchased a new position in Hologic during the 1st quarter valued at $77,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.